CoVID Treatment Centers

What CoVID Treatment Centers does

Metro Research Center, doing business as Metro Center Research and operating under the CoVID Treatment Centers brand, is a private infectious disease clinical research and care facility founded in 2022 and headquartered at 901 McClintock Drive, Suite 201, Chicago, Illinois. The company operates under the oversight of Metro Infectious Disease Consultants (MIDC), which is described as the nation's largest infectious disease group with over 100 ID physicians practicing across multiple states. The center provides patients with access to cutting-edge clinical trials and specialized outpatient treatment services across infectious disease indications including COVID-19, C. difficile (including fecal microbiota transplantation), HIV, influenza, monkeypox, RSV, and rare diseases such as ALS and hereditary disorders.

The company's core offerings combine a Clinical Trials Program (covering COVID, C. difficile, HIV, MPox, RSV, infusion, and rare disease trials) with a Patient Treatment Services line delivering outpatient antibiotic therapy and a Hospital Avoidance Program. All studies are reviewed and approved by the FDA and NIH. The technology base is fundamentally clinical — protocol-driven infectious disease research and outpatient care delivery — rather than software- or AI-driven; proprietary elements are domain-specialized care pathways and trial site capabilities rather than algorithmic assets.

Go-to-market is community-led: patient acquisition flows primarily through direct outreach and referrals from the broader MIDC physician network, with the website (metroresearchcenter.com) serving as an informational channel and appointment-request funnel. Revenue mechanics are professional-services based, with two streams: (1) clinical research services for pharmaceutical and research sponsors executing trials at the site, and (2) patient treatment services billed through outpatient care delivery. No pricing data is publicly disclosed, and the entity operates without disclosed external funding, functioning effectively as a clinical-operating subsidiary of MIDC rather than an independently capitalized startup.

Name

CoVID Treatment Centers

Legal name

Metro Research Center

Website

https://ctcmedicine.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

51–100 employees

Short description

Metro Research Center, founded in 2022 in Chicago, conducts FDA/NIH-approved clinical trials and provides outpatient treatment services for infectious diseases including COVID-19, C. difficile, HIV, influenza, monkeypox, and rare diseases, operating under Metro Infectious Disease Consultants' 100+ physician network.

Ownership category

akta.pro rank

Product category

Infectious Disease Treatment & Clinical Research Services

NAICS

All Other Outpatient Care Centers (621498), Medical Laboratories (621511)

SIC

Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Clinical Research & Trial Central Laboratories (HLAFAMAL)

akta.pro secondary industry

Central Laboratory Services (Core Lab Operations) (HLAGAEAA)

Keywords

• Infectious disease treatment
• Clinical trial services
• Outpatient infusion therapy
• COVID treatment research
• C. difficile treatment

Headquarters

HQ city

Chicago

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Research Services: Revenue generated through conducting clinical trials for pharmaceutical companies and research organizations. Studies are reviewed and approved by FDA and NIH, ensuring high standards of scientific integrity.
2. Patient Treatment Services: Treatment services for infectious diseases including C. difficile infection, COVID-19, influenza, monkeypox, and HIV. Provides outpatient antibiotic therapy and comprehensive patient care.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

CoVID Treatment Centers (also branded as Metro Research Center) is an outpatient infectious disease clinic and clinical research site that diagnoses and treats conditions such as COVID-19, C. difficile, influenza, monkeypox, HIV, and RSV, while also enrolling patients in FDA-approved and NIH-sponsored clinical trials for vaccines and therapeutics. Services are delivered by board-certified infectious disease physicians through infusion centers and a Hospital Avoidance Program, supporting both direct patient care and contracted pharmaceutical research.

Product overview

Metro Research Center is an infectious disease research and care organization offering a unified portfolio of treatment services and clinical trials. The core offering includes specialized treatments for COVID-19, C. difficile infection, influenza, and monkeypox, all integrated with access to cutting-edge clinical trials. The organization is overseen by Metro Infectious Disease Consultants and provides patients access to the latest research protocols beyond traditional academic centers. Studies undergo review by FDA and NIH, and the center implements Hospital Avoidance Programs and outpatient antibiotic therapy.

Differentiator

Problem solved

Functional benefit

Brands

• Hospital Avoidance Program: A program implemented to provide comprehensive care for patients, helping them avoid hospitalization.

Products and services

• COVID-19 Treatment Diagnosis and outpatient treatment of COVID-19, including access to investigational therapeutics through clinical trials, for patients with active or recently diagnosed COVID-19 infection.
• COVID-19 Prevention / Vaccine Booster Clinical Trial Clinical research enrollment for COVID-19 vaccine booster studies and prevention therapeutics for eligible adult participants.
• C. difficile Infection Treatment Outpatient management and treatment of Clostridioides difficile (C. diff) infections, including antibiotic therapy and supportive care delivered by infectious disease specialists.
• Influenza Treatment Outpatient diagnosis and treatment of influenza, with access to clinical trials of next-generation flu vaccines and therapeutics.
• Monkeypox (Mpox) Treatment and Vaccine Trial Treatment of monkeypox (mpox) infection plus enrollment in mpox vaccine clinical trials for eligible participants.
• HIV Clinical Research Trials Enrollment in HIV-related clinical trials offering patients access to investigational antiretroviral therapies and HIV research programs.
• RSV Clinical Research Trials Enrollment in respiratory syncytial virus (RSV) vaccine and therapeutic clinical trials for eligible adult and pediatric participants.
• Hospital Avoidance Program (Outpatient IV/Oral Antibiotic Therapy) Outpatient delivery of intravenous and oral antibiotic therapy through the Hospital Avoidance Program, enabling patients with serious infections to be treated without inpatient hospital admission, administered at Metro Infusion Center locations.
• Metro Research Center Clinical Trials Program Contracted clinical trial site services for pharmaceutical and biotech sponsors, providing patient enrollment, regulatory-compliant study execution, and investigator oversight for vaccine and therapeutic trials across multiple infectious disease indications.

Quantifiable outcome

• Expanded access to treatments beyond traditional academic centers

Named customers2 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Metro Infectious Disease Consultants (MIDC)coreStrategic or Co-development PartnerMetro Research Center is overseen by Metro Infectious Disease Consultants, the nation's largest infectious disease group with over 100 highly skilled ID physicians. This partnership provides access to extensive research experience, broad physician network, and established clinical trial infrastructure across multiple states.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• ICON plc: Global CRO with clinical research site services and laboratories (post-PRA Health Sciences merger). A broad incumbent in the clinical trial services space where Metro Research Center competes for sponsor trial placements.
• IQVIA: Global CRO and clinical research services provider with a large site network (IQVIA Prime Site program) and central lab capabilities. Functions as a broad incumbent in the same clinical trial site and services market that Metro Research Center operates in, though at vastly larger scale and scope.
• PPD (Thermo Fisher Scientific): Global CRO with extensive clinical research site footprint and central laboratory services, now part of Thermo Fisher. Competes for sponsor trial placement and central lab work that overlaps with Metro Research Center's clinical trial site operations.
• Medpace: Mid-to-large full-service CRO with site management and clinical monitoring capabilities across all major therapeutic areas including infectious disease. Operates in the same sponsor-funded clinical trial services market, though as a CRO rather than a dedicated site network.

Direct peers

• DM Clinical Research: Houston-based clinical trial site network with multiple dedicated research sites across therapeutic areas including infectious disease. Highly comparable to Metro Research Center as a multi-site investigator network running outpatient trials on behalf of pharmaceutical sponsors.
• Velocity Clinical Research: One of the largest U.S. clinical trial site networks, multi-specialty and multi-state, that operates dedicated research sites conducting Phase 1–4 trials for biopharma sponsors. Directly comparable to Metro Research Center as a fee-for-service site operator leveraging geographic and physician reach to attract trial placements.
• Accel Research Sites: Multi-specialty clinical trial site network operating across the U.S. with dedicated research facilities. Direct peer to Metro Research Center as a site-based clinical research organization recruiting patients and executing sponsor protocols in outpatient settings.
• M3 Wake Research: Large U.S. clinical trial site network (part of M3 Inc.) operating multiple dedicated research sites across multiple states, with significant infectious disease and vaccine trial experience. Closely comparable to Metro Research Center's model of physician-network-backed outpatient trial execution.
• Meridian Clinical Research: U.S. clinical trial site network with multiple dedicated research locations running Phase 1–4 trials, including infectious disease and vaccine studies. Comparable to Metro Research Center as a multi-site outpatient research operator serving biopharma sponsors.
• IMA Clinical Research: Clinical trial site network operating dedicated research facilities across multiple states with experience in infectious disease, vaccine, and chronic disease trials. Directly comparable to Metro Research Center as a site-based operator executing outpatient clinical research.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/ctcmedicine

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CoVID Treatment Centers